Pulsatile insulin of Medicine at the University of California, Davis, led the field as a pioneer of using pulsatile insulin in the treatment of diabetes. Dr. Aoki’s work focused on the role of liver dysfunction in diabetic metabolism. He theorized that end organ damage in diabetes is caused by abnormal hepatic glucose metabolism, inadequate insulin delivery, and insulin resistance. He called his approach Metabolic Activation Therapy (MAT), which consisted of an ever-increasing baseline of insulin using Respiratory Quotient to determine the efficiency of treatment (US Patent 4,826,810). Normally, insulin is secreted from the pancreas in pulses into the portal vein which brings
Insulin resistance the likelihood of Type 2 diabetes mellitus. Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels. Another factor that may promote insulin resistance is Leptin, a hormone produced from the ob gene and adipocytes. Its physiological role is to regulate hunger by alerting the body when it is full. From an adaptation perspective, it is possible that leptin resistance was favorable for survival during periods when food was scarce. Today however studies show that lack of leptin causes severe obesity and is strongly linked with insulin resistance. Leptin replacement in mice with